Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy
- 1 October 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Oncology
- Vol. 3 (10), 564-574
- https://doi.org/10.1038/ncponc0610
Abstract
Growing evidence supports the concept of oncogene dependence for cancer development; inhibition of the initiating oncogene can result in revertion of the neoplastic phenotype. The outstanding role of the RET proto-oncogene in the development of medullary thyroid carcinoma (MTC) is well established. With the emerging knowledge concerning the signal transduction pathways leading to subsequent neoplastic transformation, oncogenic activated RET becomes a highly attractive target for selective cancer therapy. A variety of novel approaches that target RET directly or indirectly have recently emerged and an increasing number are currently being assessed in clinical trials. In view of these findings, it becomes strikingly obvious that inhibition of RET oncogene function can be a viable option for the treatment of MTC. We summarize the current evidence for RET involvement in the etiology of MTC, and the therapeutic targeting of this process in preclinical and clinical studies.Keywords
This publication has 68 references indexed in Scilit:
- Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine KinasePLoS Biology, 2005
- The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cellsThe Journal of cell biology, 2004
- Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsOncogene, 2004
- RAS and RHO GTPases in G1-phase cell-cycle regulationNature Reviews Molecular Cell Biology, 2004
- Beyond Herceptin and GleevecCurrent Opinion in Chemical Biology, 2003
- Coordinated Activation of Autophosphorylation Sites in the RET Receptor Tyrosine KinasePublished by Elsevier BV ,2002
- TrastuzumabDrugs, 2002
- MEN2A-RET-induced cellular transformation by activation of STAT3Oncogene, 2001
- C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RETOncogene, 2001
- Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell LineBiochemical and Biophysical Research Communications, 1995